article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

1ne: A new analysis predicts that by 2030, 48.9% Increased provider consolidation has decreased individual market competition, in which lower prices, improved productivity, and innovation can occur. Without this competition, these near-monopolies have providers and insurers in a position where they can drive up their prices unopposed.

article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

The two companies said the transaction is expected to close by the end of 2022, subject to approval by the competition authorities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. Omega Therapeutics’s share suggests increasing competition and diversification in this innovative field,” concluded Podder. Global RNA therapy clinical trials market to reach $3.5 subvariant.

Marketing 110
article thumbnail

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Pharmaceutical Technology

4DMT is creating a gene therapy using an adeno-associated viral vector (AAV) and there is currently competition from several early-stage therapies in trial, such as Sangamo Therapeutics’s Fabry gene therapy that is currently at Phase III, which also uses AAV, and as of November 2022 has reported it is progressing to late-stage plans.

FDA 105
article thumbnail

Vaccines Europe launches first pipeline review

European Pharmaceutical Review

The time to population access for vaccines exceeds six years in a third of States, and the procurement mechanism for vaccines in most States doesn’t facilitate fair competition, timely access to vaccines and sustainable supply. The pipeline review determined there are disparities in market access to vaccines across Europe.

article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98
article thumbnail

Sun Pharma agrees deal to buy alopecia player Concert

pharmaphorum

Deuroxilitinib (formerly CTP-543) – a JAK 1/2 inhibitor – is coming up against drugs in the class from Eli Lilly and Pfizer in the alopecia areata market, so will face heavyweight competition, although Sun reckons it is a “best in class” therapy. The report predicts that the alopecia areata market will grow to as much as $2.5

Pharma 98